MDxHealth Shareholder Transparency Declaration
03 Octobre 2019 - 7:00AM
Press release
Regulated information
3 October 2019, 7 a.m. CEST
IRVINE, CA, and HERSTAL,
BELGIUM – 3 October 2019 – MDxHealth SA (Euronext
Brussels: MDXH) (the “Company” or
"MDxHealth"), a commercial-stage innovative
molecular diagnostics company, announced that it received the
following notification of a significant shareholding in accordance
with the Belgian Act of 2 May 2007 on the disclosure of important
participations in issuers of which shares are admitted to trading
on a regulated market and regarding miscellaneous
provisions.
Scorpiaux BVBA notified MDxHealth of the
acquisition of voting rights attached to securities in MDxHealth,
as a result of which, on 27 September 2019, its participation in
MDxHealth increased above the threshold of 5% of the outstanding
shares and voting rights of MDxHealth. Notably, it follows from the
notification that Scorpiaux BVBA owns 3,867,776 shares of
MDxHealth, representing 5.48% of the 70,528,525 outstanding shares
and voting rights of MDxHealth. The notification states that
Scorpiaux BVBA is exclusively controlled by Bart Versluys in the
sense of articles 5 and 7 of the Belgian Companies Code, and that
Scorpiaux BVBA, together with a third party, has control, in the
sense of articles 5 and 7 of the Belgian Companies Code, over
Versluys Invest BVBA.
For further information, reference is made to
the information published on MDxHealth's website
(http://www.mdxhealth.com/investors/shareholder-information).
About MDxHealth®
MDxHealth is a multinational healthcare company
that provides actionable molecular diagnostic information to
personalize the diagnosis and treatment of cancer. The Company's
tests are based on proprietary genetic, epigenetic (methylation)
and other molecular technologies and assist physicians with the
diagnosis of urologic cancers, prognosis of recurrence risk, and
prediction of response to a specific therapy. The Company's
European headquarters are in Herstal, Belgium, with laboratory
operations in Nijmegen, The Netherlands, and US headquarters and
laboratory operations based in Irvine, California. For more
information, visit mdxhealth.com and follow us on social media at:
twitter, facebook and linkedin.
For more information:
Amber Fennell, Chris Welsh, Nicholas Brown Consilium Strategic
CommunicationsUK: +44 20 3709 5700mdxhealth@consilium-comms.com
Important Information:
The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are
trademarks or registered trademarks of MDxHealth SA (the "Company"
or " MDxHealth"). All other trademarks and service marks are the
property of their respective owners.
MDxHealth (EU:MDXH)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
MDxHealth (EU:MDXH)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024